Curis (CRIS) Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRIS shares.
View CRIS analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 1 year price objectives for Curis' stock. Their CRIS share price forecasts range from $9.00 to $9.00. On average, they expect the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 990.9% from the stock's current price.
View analysts price targets for CRIS or view top-rated stocks among Wall Street analysts.

Curis' stock was trading at $0.55 on January 1st, 2023. Since then, CRIS stock has increased by 50.0% and is now trading at $0.8250.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CRIS earnings forecast.

Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings results on Thursday, May, 4th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.01. The biotechnology company earned $2.30 million during the quarter, compared to the consensus estimate of $2.49 million. Curis had a negative trailing twelve-month return on equity of 103.76% and a negative net margin of 501.08%. During the same period in the prior year, the business earned ($0.18) earnings per share.

Curis shares reverse split before market open on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 29th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).

Curis trades on the NASDAQ under the ticker symbol "CRIS."

Curis' stock is owned by many different retail and institutional investors. Top institutional investors include Maverick Capital Ltd. (5.73%), Citigroup Inc. (1.90%), Renaissance Technologies LLC (1.68%), BlackRock Inc. (1.44%), Two Sigma Advisers LP (0.64%) and CM Management LLC (0.57%).
View institutional ownership trends.

Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRIS stock can currently be purchased for approximately $0.83.

Curis (NASDAQ:CRIS) has a market capitalization of $79.71 million and generates $10.16 million in revenue each year. The biotechnology company earns $-56,670,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The official website for the company is www.curis.com. The biotechnology company can be reached via phone at (617) 503-6500, via email at info@curis.com, or via fax at 617-503-6501.